Findings
The most promising aspects of mental health for digital measurement are sleep, physical activity, stress, and social behavior, which have the strongest scientific evidence. Core barriers to adoption include high cost and limited access, data privacy concerns, poor technological literacy, and a lack of technology adaptation for specific mental health needs. Essential technology characteristics for "fit-for-purpose" sDHTs include usability, reliable performance, strong data privacy and security, and long battery life.

Recommendations
Research and development should prioritize moving promising measures (sleep, activity, stress, social behavior) to large-scale clinical trials. Algorithms must be refined and clinically validated for mental health indications, and new sensor modalities should be explored. Infrastructure must be developed by creating standards and ontologies for mental health sensor data to ensure interoperability and scalability. To improve access and equity, financial support mechanisms and inclusive, culturally tailored design are critical.

Regulatory Considerations
The report does not provide a separate section for "Regulatory Considerations" but emphasizes that future development and funding should prioritize clinical validation across diverse populations. It notes the importance of a clear understanding of the intended measurement claims and the need for rigorous validation studies to move beyond pilot and feasibility stages to demonstrate real-world clinical utility.

Findings
Challenges in patient adherence and acceptability of digital endpoints.
Issues with algorithm validation and use in diverse populations.
Barriers due to proprietary software and lack of transparency.
Vast heterogeneity in digital endpoints and lack of standards.
Need for ongoing ethical support and consideration of environmental impact.

Recommendations
Foster multi-stakeholder cooperation and open-forum discussions.
Integrate patient needs into the design of digital health technologies.
Include implementation science expertise in research proposals.
Develop standards for selecting and reporting digital endpoints.
Provide ongoing ethical support throughout the research lifecycle.

Regulatory Considerations
Early engagement with regulators is crucial.
Understanding regulatory requirements for clinical trials versus clinical care.
Need for harmonised terminology and guidelines for digital endpoints.

Findings
Sufficient resources must be allocated, including infrastructure costs, training, and site reimbursement, to ensure smooth PT deployment.
PTs must be intuitive, validated, and able to withstand technical or environmental challenges to avoid burdening patients and sites.
PTs must comply with data privacy laws (e.g., GDPR, HIPAA) and regulatory standards (e.g., 21 CFR Part 11), and address import restrictions and age limitations.
Scaling PTs requires plans for device maintenance, multilingual support, and consistent availability across geographies and populations.
Sites need adequate training, realistic responsibilities, and clear workflows to avoid overburdening site staff and ensure patient compliance.

Recommendations
Involve key stakeholders (e.g., clinical technologies, regulatory affairs, site relations) early in the planning process to address potential challenges.
Identify risks related to usability, compliance, and data integrity, and establish mitigation strategies before implementation.
Provide tailored training materials for patients and site staff, ensuring clarity and accessibility in multiple formats and languages.
Develop Clear Vendor Contracts: Clearly outline responsibilities for maintenance, data management, and support in vendor contracts to avoid operational ambiguities.
Create Scalability Plans: Address challenges like multilingual support, long-term device maintenance, and cross-region deployment during the initial planning stages.

Regulatory Considerations
Ensure PTs comply with GDPR, HIPAA, and other relevant data protection regulations, particularly in global trials.
Verify if PTs qualify as medical devices and adhere to corresponding regulatory frameworks.
Assess and plan for country-specific import restrictions and data privacy laws to avoid delays.
Validate PTs according to Good Clinical Practice (GCP) guidelines, ensuring reliable data generation and compliance with regulatory standards.
Account for age-related legal restrictions, ensuring PTs are suitable for all intended patient populations.

Findings
Successful PT implementation requires iterative planning across six stages to adapt to changing study goals and patient needs.
Early engagement with patients, caregivers, sites, and regulatory bodies is critical to align PT goals with stakeholder priorities.
Identifying technical, operational, and compliance risks early on is essential for smooth implementation and scalability.
Rapid, small-scale tests of technologies can help address unknowns, refine user experience, and mitigate technical risks before full-scale pilots.
Scaling PT across geographies and populations requires addressing regional variations in infrastructure, regulations, and cultural acceptance.

Recommendations
Start with a clear, organization-wide PT strategy to align with clinical trial goals and define success metrics.
Involve patients, sites, and regulatory authorities early to gather insights and ensure alignment with their needs and priorities.
Test technologies in controlled environments to validate functionality, usability, and integration before pilot studies.
Use technology pilots to collect data on feasibility, usability, and implementation challenges to inform broader rollouts.
Leverage learnings from pilots to develop a scalable strategy that addresses technical, regulatory, and cultural barriers.

Regulatory Considerations
Determine whether the technology is classified as a medical device and ensure compliance with relevant regulations (e.g., FDA, EMA, MDR).
Address data protection regulations, such as GDPR, by implementing robust privacy measures and secure data storage practices.
Account for region-specific regulatory requirements and infrastructure challenges during scaling.
Proactively consult regulatory agencies during pilots to align on technology use, endpoints, and data validity.